Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $9.00 Average Price Target from Brokerages

Shares of Senti Biosciences, Inc. (NASDAQ:SNTI) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $9.00.

Several analysts have recently issued reports on the company. Leerink Partners started coverage on Senti Biosciences in a research report on Friday, November 21st. They issued an “outperform” rating and a $6.00 price objective on the stock. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. Finally, Chardan Capital lifted their price target on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th.

Senti Biosciences Stock Performance

Shares of NASDAQ:SNTI opened at $0.95 on Friday. The business’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.45. The stock has a market cap of $25.00 million, a PE ratio of -0.29 and a beta of 2.12. Senti Biosciences has a one year low of $0.80 and a one year high of $5.10.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNTI. Jane Street Group LLC acquired a new stake in shares of Senti Biosciences during the fourth quarter worth $40,000. Virtu Financial LLC purchased a new position in Senti Biosciences during the fourth quarter worth about $46,000. Citadel Advisors LLC acquired a new stake in Senti Biosciences in the 3rd quarter worth about $117,000. Geode Capital Management LLC boosted its stake in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in Senti Biosciences in the 2nd quarter valued at about $1,883,000. 25.70% of the stock is currently owned by institutional investors and hedge funds.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.